Oncology

Information for...

General Use Patients or Carers Health Care Professionals in the US Health Care Professionals outside the US and UK Journalists Jobseekers

Press Releases

Note: This webpage hosts content for general public as well as for healthcare professional and journalists & media professionals. To be able to see and access respective content you need to select your profession through the filter button on the right.

PRESS RELEASE 10 Dec 2020 at 14:00

Boehringer Ingelheim to acquire NBE-Therapeutics

Read more on Boehringer Ingelheim to acquire NBE-Therapeutics
PRESS RELEASE 09 Dec 2020 at 10:00

Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen

Read more on Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen
PRESS RELEASE 07 Dec 2020 at 14:00

Collaboration with Proxygen on Molecular Glue Degraders

Read more on Collaboration with Proxygen on Molecular Glue Degraders
PRESS RELEASE 14 Oct 2020 at 14:00

Expanded alliance with OBT advances cancer immunology pipeline

Read more on Expanded alliance with OBT advances cancer immunology pipeline
PRESS RELEASE 17 Sep 2020 at 14:00

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

Read more on BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR
PRESS RELEASE 10 Sep 2020 at 14:00

Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers

Read more on Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
PRESS RELEASE 07 Jul 2020 at 14:00

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

Read more on Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases
PRESS RELEASE 16 Mar 2020 at 09:00

New uncommon EGFR mutations database published featuring clinical outcomes of NSCLC patients treated with afatinib

Read more on New uncommon EGFR mutations database published featuring clinical outcomes of NSCLC patients treated with afatinib
PRESS RELEASE 12 Aug 2019 at 15:00

Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies

Read more on Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies
PRESS RELEASE 02 Aug 2019 at 11:30

Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Read more on Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
PRESS RELEASE 17 Jun 2019 at 18:00

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Read more on Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
PRESS RELEASE 11 Jun 2019 at 14:00

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Read more on Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
PRESS RELEASE 29 Mar 2019 at 13:00

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Read more on Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
PRESS RELEASE 15 Nov 2018 at 12:30

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies

Read more on Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
PRESS RELEASE 19 Oct 2018 at 12:00

Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC

Read more on Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
PRESS RELEASE 13 Sep 2018 at 08:00

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies

Read more on Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology Therapies
PRESS RELEASE 25 Apr 2018 at 13:30

Boehringer Ingelheim R&D pushes to transcend disease boundaries

Read more on Boehringer Ingelheim R&D pushes to transcend disease boundaries
Cancer Immunology Innovation Approach

PRESS RELEASE 04 Apr 2018 at 18:00

New Immuno-Oncology Partnership with OSE Immunotherapeutics to Develop a Pioneering Checkpoint Inhibitor

Read more on New Immuno-Oncology Partnership with OSE Immunotherapeutics to Develop a Pioneering Checkpoint Inhibitor
Electron micrograph of VSV-GP

PRESS RELEASE 28 Sep 2016 at 14:00

BOEHRINGER INGELHEIM BOOSTS IMMUNE-ONCOLOGY PIPELINE THROUGH COLLABORATION WITH VIRATHERAPEUTICS

Read more on BOEHRINGER INGELHEIM BOOSTS IMMUNE-ONCOLOGY PIPELINE THROUGH COLLABORATION WITH VIRATHERAPEUTICS

Search form

Oncology

Press Releases